1. U.S. National Library of Medicine. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ [Website].
2. European Medicine Agency. Committee for Medicinal Products for Human Use (CHMP) Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev 1/ Corr **. 2010 January 20 . Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf [Website].
3. Karalis V, Macheras P. An insight into the properties of a two-stage design in bioequivalence studies. Pharm Res. 2013;30(7):1824–35 [Journal Article].
4. Food and Drug Administration. Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry. 2019 November. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry [Website].
5. European Medicine Agency. Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned With an Adaptive Design. EMEA Doc Ref CHMP/EWP/2459/02. 2007 October 18. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-methodological-issues-confirmatory-clinical-trials-planned-adaptive-design_en.pdf [Website].